Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Total Debt (2020 - 2026)

GeneDx Holdings has reported Total Debt over the past 7 years, most recently at $96.7 million for Q1 2026.

  • Quarterly Total Debt rose 86.76% to $96.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $96.7 million through Mar 2026, up 86.76% year-over-year, with the annual reading at $48.2 million for FY2025, 7.2% down from the prior year.
  • Total Debt was $96.7 million for Q1 2026 at GeneDx Holdings, up from $48.2 million in the prior quarter.
  • Over five years, Total Debt peaked at $96.7 million in Q1 2026 and troughed at $6.1 million in Q3 2023.
  • The 5-year median for Total Debt is $51.6 million (2025), against an average of $37.3 million.
  • Year-over-year, Total Debt crashed 53.2% in 2023 and then soared 759.78% in 2024.
  • A 5-year view of Total Debt shows it stood at $9.8 million in 2022, then surged by 435.28% to $52.7 million in 2023, then dropped by 1.47% to $51.9 million in 2024, then dropped by 7.2% to $48.2 million in 2025, then soared by 100.79% to $96.7 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Total Debt are $96.7 million (Q1 2026), $48.2 million (Q4 2025), and $51.6 million (Q3 2025).